LongeVC’s Sergey Jakimov’s Op-Ed Published in EU VC
Europe has a unique opportunity to lead the global biotech revolution, with a thriving landscape of innovators and diverse funding opportunities. However, transforming R&D breakthroughs into economic success requires more than just resources—it demands a strategic focus on incentivising innovation and streamlining IP commercialisation processes.
In a recent op-ed for EUVC, Sergey Jakimov, Managing Partner at LongeVC, highlights how Europe can replicate and scale success stories like Novo Nordisk’s Ozempic-driven economic impact. Sergey’s insights offer a roadmap for aligning stakeholders across academia, industry, and investment to create a sustainable ecosystem for biotech growth.